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The impact of SARS-CoV-2 in regions endemic for both Dengue and Chikungunya is still not
fully understood. Considering that symptoms/clinical features displayed during Dengue, Chi-
kungunya and SARS-CoV-2 acute infections are similar, undiagnosed cases of SARS-CoV-
2 in co-endemic areas may be more prevalent than expected. This study was conducted to
assess the prevalence of covert cases of SARS-CoV-2 among samples from patients with
clinical symptoms compatible with either Dengue or Chikungunya viral infection in the state
of Espı́rito Santo, Brazil.
Methods
Presence of immunoglobulin G (IgG) antibody specific to SARS-CoV-2 nucleoprotein was
detected using a chemiluminescent microparticle immunoassay in samples from 7,370
patients, without previous history of COVID-19 diagnosis, suspected of having either Den-
gue (n = 1,700) or Chikungunya (n = 7,349) from December 1st, 2019 to June 30th, 2020.
Findings
Covert cases of SARS-CoV-2 were detected in 210 (2.85%) out of the 7,370 serum samples
tested. The earliest undiagnosed missed case of COVID-19 dated back to a sample col-
lected on December 18, 2019, also positive for Dengue Virus. Cross-reactivity with either
Dengue virus or other common coronaviruses were not observed.
Interpretation
Our findings demonstrate that concomitant Dengue or Chikungunya outbreaks may difficult
the diagnosis of SARS-CoV-2 infections. To our knowledge, this is the first study to
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demonstrate, with a robust sample size (n = 7,370) and using highly specific and sensitive
chemiluminescent microparticle immunoassay method, that covert SARS-CoV-2 infections
are more frequent than previously expected in Dengue and Chikungunya hyperendemic
regions. Moreover, our results suggest that SAR-CoV-2 cases were occurring prior to Feb-
ruary, 2020, and that these undiagnosed missed cases may have contributed to the fast
expansion of SARS-CoV-2 outbreak in Brazil. Data presented here demonstrate that in
arboviral endemic regions, SARS-CoV-2 infection must be always considered, regardless of
the existence of a previous positive diagnosis for Dengue or Chikungunya.
Introduction
In December 2019, after several cases of severe pneumonia of unknown etiology emerged in
China, the causative agent was y identified as SARS-CoV-2 (Severe Acute Respiratory Syn-
drome Coronavirus 2), a member of Coronaviridae family (Betacoronavirus genus) and asso-
ciated with the onset of a severe respiratory disease termed “COVID-19” (COronaVIrus
Disease 2019) [1–3]. In a matter of weeks, the SARS-CoV-2 outbreak spread rapidly, reaching
nearly every country in the World, and compelling the World Health Organization (WHO) to
declare COVID-19 a global pandemic by March 11th, 2020 [1, 4]. As of December 15, 2020, a
cumulative total of nearly 71.3 million cases and 1,612,372 deaths have been reported since the
start of the outbreak [5]. In Brazil, the first confirmed case of SARS-CoV-2 infection was
announced by the Brazilian Ministry of Health on February 26, 2020; currently occupying the
third place worldwide in number of cases, contributing with over 6.9 million cases and close to
181,835 deaths [6].
Symptoms associated with SARS-CoV-2 infection vary widely, from asymptomatic disease
to multisystem organ failure and, even death [7]. However, in most cases, patients have few or
no symptoms posing a challenge to prevent disease dissemination. The fast expansion of
COVID-19 raised several public health concerns, one of them is associated with the possibility
of misdiagnosing SARS-CoV-2 infections in regions where arboviral diseases, such as Dengue
fever or Chikungunya, are concomitantly endemic [8]. In Brazil, endemic arboviral diseases
have led to seasonal large scale outbreaks resulting in high rates of morbidity and mortality in
the past two decades. Emergence of SARS-CoV-2 in arboviral–endemic areas has raised con-
cerns regarding coinfection with the two viruses and the occurrence of misdiagnosis.
From November 1st, 2019 to March, 2020, while the first cases of SARS-CoV-2 were emerg-
ing across the globe, positive cases of Dengue and Chikungunya were soaring throughout Bra-
zil. In the state of Espı́rito Santo it was not different. At the same time, 18.73% and 67.9% of
individuals suspected of having either acute Dengue or Chikungunya infection, respectively,
were positive for SARS-CoV-2 IgG. Parallelly, the first official known COVID-19 case in the
state of Espı́rito Santo was reported on March 4th, 2020. A current threat in several countries,
the impact on public health of concomitant Dengue, Chikungunya and COVID-19 outbreaks
is still not fully understood. It has been reported that acute cases initially diagnosed as Dengue
were later confirmed to be caused by SARS-CoV-2 [9–11]. Considering that the similarity of
symptoms/clinical features shared by Dengue, Chikungunya and SARS-CoV-2 infections, it is
fair to assume that misdiagnosis in co-endemic areas may be more prevalent than expected,
especially when the majority of diagnosed cases are mainly based on clinical-epidemiological
observations. Therefore, failing to consider SARS-CoV-2, as the etiological agent, due to the
existence of a positive Dengue or Chikungunya test result may have serious consequences for
both the patient and public health.
PLOS ONE Covert SARS-CoV-2 positive cases among Dengue and Chikungunya patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0244937 January 6, 2021 2 / 21
In the present work, we investigated the hypothesis that early covert SARS-CoV-2 cases
were missed and that its diagnosis may have been hindered by an existing clinical or laborator-
ial diagnosis of acute Dengue or Chikungunya infections, in regions endemic for arboviral dis-
eases. In order to confirm our hypothesis, serum samples from patients suspected of having
Dengue or Chikungunya were re-tested for the presence of anti-SARS-CoV-2 antibodies,




Serum samples from 7,370 patients with clinical symptoms compatible with either Dengue
fever or Chikungunya were collected between December 1st, 2019 and June 30th, 2020 and
tested for the presence of anti-SARS-CoV-2-nucleoprotein IgG antibodies. Inclusion criteria
were: 1) samples from subjects with clinical symptoms compatible with Dengue and/or Chi-
kungunya infection, 2) residents of the state of Espı́rito Santo, and 3) subjects with no prior
history of COVID-19 diagnosis. Samples were anonymized prior to their inclusion in the
study. SARS-CoV-2 IgG immunoreactivities were analyzed at the Espı́rito Santo’s Central Pub-
lic Health Laboratory (LACEN-ES). Demographic data and laboratory results, including sam-
ple results (S), cutoff values (CO), and result Index values (S/CO) were obtained prior
anonymization from laboratory information management database (Gerenciador de
Ambiente Laboratorial–GAL, DATASUS, Ministry of Health).
Ethics statement
LACEN-ES belongs to public health laboratories network coordinated by Brazilian Ministry of
Health and is part of the state of Espı́rito Santo’s Secretary of Health. All samples used in the
present work were stored at -80˚C and after routine diagnosis for either Dengue or Chikungu-
nya at the Immunology Division of Laboratório Central do Espı́rito Santo (LACEN-ES). The
availability of these samples for research purpose during outbreaks is supported by Resolution
number 510/2016 of the National Ethical Committee for Research–Brazilian Ministry of
Health (CONEP–Comissão Nacional de Ética em Pesquisa, Ministério da Saúde, Brasil):
which authorizes the use of clinical samples collected in the Brazilian Central Public Health
Laboratories to accelerate the understanding, further the knowledge, contribute to public
health surveillance and fast responses during outbreaks, epidemics or pandemic, such as the
one observed for COVID-19.
Detection of Chikungunya- and Dengue-specific IgM antibodies by ELISA
All samples used in the present work were previously tested for the presence of both Chikun-
gunya and Dengue specific IgM antibodies by means of enzyme-linked immunosorbent assay
(ELISA). Chikungunya diagnosis was carried out using an anti-Chikungunya virus ELISA
(IgM) Test (cat #. EI 293a-9601 M, Euroimmun, Luebeck, Germany). ELISA sensitivity and
specificity, according to the manufacturer, are 98.1% and 99.9%, respectively. For the Dengue
diagnosis, samples were assayed using the anti-Dengue virus ELIS (IgM) Test (cat no. EI 266b-
9601-1 M, Euroimmun, Luebeck, Germany). This test contains a microplate coated with viral
particles and recombinant glycoprotein E (DEN 1–4). According to the manufacturer, sensi-
tivity, and specificity, is 100% and 98%, respectively. Results interpretation for both assays
were identical: values� 0.8 were considered negative; between 0.8 and 1.1 borderline/
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inconclusive, and those� 1.1 positive. Samples with borderline/inconclusive results were
retested and the second result analyzed.
Detection of SARS-CoV-2 IgG antibodies by chemiluminescent
microparticle immunoassay
Presence of IgG specific to SARS-CoV-2 nucleocapsid protein N was detected by a highly spe-
cific and sensitive chemiluminescent microparticle immunoassay (CMIA, Abbott Laboratories
SARS-CoV-2 IgG immunoassay, Abbott Park, IL). The Abbott Laboratories SARS-CoV-2 IgG
assay is a two-step qualitative CMIA which employs acridinium ester-mediated chemilumines-
cence and is performed on the Architect i2000SR automated immunoassay analyzer. Testing
was performed in accordance with the manufacturer’s instructions. The cutoff index (S/CO) is
1.4 and was calculated by dividing sample result (S) by the stored calibrator result (CO). Index
�1.4 are considered positive, and Index < 1.4 are negative. Positive Percent Agreement (PPA)
was 86.5% (95%CI: 65.09–97.09) for samples collected between 8–13 days post-symptom onset
and 100% (95%CI: 95.89–100%) for those collected�14 days. Negative Percent Agreement
(NPA) was 99.63% (95%CI: 99.05–99.90%). Results from 16 samples positive for IgG to
SARS-CoV-2 collected between December 2019 and February, 2020 were confirmed using
MAGLUMI™ 2019-nCoV IgG and IgM kits on a MAGLUMI™ 800 (Snibe, China), specific for
both SARS-CoV-2 N and S proteins (sensitivity 80%, 95% CI:63–90; specificity: 99%, 95% CI:
92–100).
Pre-SARS-CoV-2 pandemic Dengue positive serum samples
A pre-SARS-CoV-2-pandemic serum panel was used to assess Dengue and SARS-CoV-2
cross-reactivity. These samples were obtained from symptomatic, Dengue PCR positive
patients, collected between 2009 and 2010 and stored at -80˚C at the Núcleo de Doenças Infec-
ciosas, Universidade Federal do Espı́rito Santo, UFES, Vitória, BRAZIL. A total of 84 serum
samples (acute and convalescent paired sera) from 42 individuals (average age ± SD = 35.5 ±12
years, range 16–64 years; 16 males, and 26 females) was available. Dengue fever was confirmed
by the detection of the viral genome by PCR and by multiple serology testing IgM and IgG
ELISA (Table 1).
Statistical analyses
Statistical analyses were performed using GraphPad PRISM version 8.01 (GraphPad Software).
ANOVA’s and Student’s t test were also performed. Categorical variables were compared
using Fisher’s exact test and continuous variables with the Mann-Whitney U test. A p
value� 0.05 was judged statistically significant. Spearman’s correlation (rho value) was used
to assess the relation between age and immunoreactivity Index (S/CO) and time post-symp-
tom onset and immunoreactivity Index (S/CO).
Role of the funding source
The funders facilitated data acquisition but had no role in the design, analysis, interpretation,
or writing. The first two authors and the senior author (RR-R) had full access to all the data.
The first four authors and the senior author (RR-R) have final responsibility for the decision to
submit for publication.
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Results
Considering that SARS-CoV-2 diagnosis in arboviruses hyperendemic regions could be chal-
lenging, prevalence of covert cases of SARS-CoV-2 was investigated in patients with acute
symptoms compatible with either Dengue or Chikungunya infection, regardless of their previ-
ous arboviral serology result (n = 7,370). General characteristics of the studied population are
given on Table 2. Serum samples from patients presenting symptoms compatible with either
Dengue fever (n = 1,700) or Chikungunya (n = 7,349) infections, originally tested for the pres-
ence of specific IgM antibodies, were included in the present study (Fig 1A). IgM positivity
rate in Chikungunya on samples collected from December, 2019 to June, 2020 was sustained
high (69–79%), whereas among Dengue samples it was lower (11 to 28%) (Fig 1B). When the
first SARS-CoV-2 case was officially announced by the Brazilian Ministry of Health on Febru-
ary 26th, 2020, incidence of Dengue and Chikungunya infections were soaring in the state of
Espı́rito Santo. Soon after, on March 4th, the first case was reported in the state of Espı́rito
Santo, skyrocketing to 19,761 cases by June 30 (Fig 1A); and from March to June 2020, SARS--
CoV-2 positivity rate jumped from 7.4 to 56.7% (Fig 1B). No significant difference regarding
age or gender distribution were observed when Dengue and Chikungunya groups were com-
pared. Conversely, antibody positivity rate in Dengue and Chikungunya groups diverged;
while presence of anti-Dengue IgM was confirmed on 228 (13.4%%) out of 1,700 samples
tested, Chikungunya specific IgM antibodies were detected on 5,244 (74.4%) out of 7,349 sam-
ples (Table 2).
As depicted in Table 3, when samples were tested for the presence of anti-SARS-CoV-2 IgG
antibodies 210 (2.85%) samples were positive; 133 (63.3%) were obtained from female patients
aging 44.4 ± 17.3 years (average ± SD), while 77 (36.7%) were males aging 46.0 ± 14.8 years
(average ± SD). Even though, female patients who tested for Chikungunya presented IgM
immunoreactivity index values higher than those observed for males (p = 0.0067), gender did
not affect either Dengue or SARS-CoV-2 IgG immunoreactivity indexes (Fig 2A–2C). Positiv-
ity rate for anti-SARS-CoV-2 IgG antibodies in the studied samples increased significantly
from December 2019 (0.49%) to June 2020 (38.1%) (Fig 2D), nonetheless differences were not
observed when SARS-CoV-2 IgG immunoreactivity index values were categorized by days-
post-symptom onset or by age (Fig 2E and 2F). Additionally, no correlation between SARS--
CoV-2 IgG immunoreactivity index and either days-post-symptom onset or age was found
(Fig 3A and 3B). To exclude the possibility that the observed SARS-CoV-2 positive results
were due to cross-reactivity with Dengue antibodies, as reported elsewhere [10, 12], a panel of
Table 2. General characteristics of the studied population.
Groups Tested for Chikungunya Tested for Dengue Total Patients�
n (%) 7,349 (99.72%) 1,700 (23.07%) 7,370 (100%)
Number of samples positive for arboviral disease
(%)
5,244 (71.35%) 228 (13.41%) 5,472 (74.25%)
Age (years) Average ± SD 45.7 ± 17.25 41.3 ± 18.99 45.8 ± 17.26
Gender distribution n (%) Female Male Female Male Female Male
4,967 (67.6%) 2,382 (32.4%) 1,089 (67.5%) 600 (35.9%) 4,977 (67.5%) 2,393 (32.5%)
Age/group (years) Average ± SD 46.2 ± 16.5 44.8 ± 18.7 57.6 ± 16.7 48.4 ± 19.0 46.2 ± 16.5 44.8 ± 18.7
Serology Results Reactive Samples n (%) 3,625 (72.34%) 1,619 (67.66%) 139 (12.76%) 89 (14.57%) 3,626� (72.8%) 1,622� (67.78%)
Non-reactive Samples n (%) 1,282 (25.76%) 731 (30.55%) 873 (80.17%) 479 (78.4%) 1,290� (25.9%) 739� (30.88%)
Inconclusive Samples n (%) 60 (1.21%) 32 (1.5%) 77 (7.07%) 43 (7.04%) 61� (1.23%) 32� (1.34%)
�—Serology results for the Total Patients’ group included samples from patients with clinical symptoms compatible with Chikungunya and/or Dengue.
https://doi.org/10.1371/journal.pone.0244937.t002
PLOS ONE Covert SARS-CoV-2 positive cases among Dengue and Chikungunya patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0244937 January 6, 2021 7 / 21
PLOS ONE Covert SARS-CoV-2 positive cases among Dengue and Chikungunya patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0244937 January 6, 2021 8 / 21
pre-pandemic samples originated from a 2009−2010 Dengue outbreak in the state of Espı́rito
Santo, including paired acute and convalescent phase sera from 42 Dengue fever patients
(Table 1), was evaluated by CMIA. All 84 samples were negative for anti-SARS-CoV-2 IgG
(Fig 4A and 4B), excluding the possibility of result misinterpretation caused by false-positive
reactions.
Antibodies to SARS-CoV-2 16 were detected on samples collected before the first COVID-
19 case was confirmed in Brazil, February 27, 2020 (Table 4). Furthermore, the earliest SARS--
CoV-2 positive case, found in the studied population, dates back to December, 2019 and is rep-
resented by a sample by a 60-year-old female patient from Vitória exhibiting symptoms
compatible with Dengue fever on December 9th 2019, who had a blood sample taken on
December 18th, testing positive for the presence of Dengue-specific IgM (S/CO = 4.31). How-
ever, when the same sample was evaluated for the presence of anti-SARS-CoV-2 IgG it was
also positive (IgG S/CO = 2.24) (Table 4). To exclude the possibility that results were due to
antigenic cross-reactivity with common coronaviruses, these 16 positive samples were also
screened using a different CLIA method (Snibe Diagnostic, China—Maglumi2000 Plus
2019-nCov IgM and IgG assays). Anti-SARS-CoV-2 IgG and IgM were detected in 7 (43.8%)
and 1 (6.3%) out of the 16 samples tested, respectively (Table 4), confirming that patients were
exposed to SARS-CoV-2 earlier than officially announced in Brazil.
In 2019, the population of the state of Espı́rito Santo state was estimated in 4,018,650
inhabitants. Our data showed that the highest number (n = 78, 37.1%) of SARS-CoV-2
positive cases were found in the capital city of Espı́rito Santo state, Vitoria, followed by the
cities of Serra (n = 25, 11.9%), Cachoeiro do Itapemirim (n = 22, 10.5%), Vila Velha
(n = 15, 7.1%), Viana (n = 13, 6.2%) and Guarapari (n = 6, 2.9%) (Fig 5). It is noteworthy
to point out that from November, 2019 to June, 2020 the incidence of Dengue and Chikun-
gunya was concomitant high in cities listed above. When Dengue, Chikungunya and
SARS-CoV-2 data were compared, it became clear that co-positive cases, SARS-CoV-2/
Dengue and SARS-CoV-2/Chikungunya, predominated from December, 2019 to January
2020 (Fig 6A). However, as the COVID-19 outbreak gained strength, frequency of SARS--
CoV-2-only cases (patient positive for anti-SARS-CoV-2 IgG but negative for both Dengue
Fig 1. Characteristics of the Dengue, Chikungunya and SARS-CoV-2 outbreaks in the state of Espı́rito Santo from
October 2019 to June 2020. A) Number of Dengue, Chikungunya and SARS-CoV-2 positive cases in Espı́rito Santo over
time; B) Positivity rate of Dengue, Chikungunya and SARS-CoV-2 cases over time.
https://doi.org/10.1371/journal.pone.0244937.g001
Table 3. Characteristics of the SARS-CoV-2 IgG positive population.




Total Patients (n = 7,370)
Presence of anti-SARS-CoV2 IgG� (%) 176 (2.39%) 85 (5.00%) 210 (2.85%)
Patients positive for SARS-CoV2 and arboviruses�� (%) 68 (38.63%) 11 (12.94%) 79 (37.62%)
Immunoreactivity/Gender Female Male Female Male Female Male
Gender (%) 49 (72.1%) 19 (27.9%) 7 (63.6%) 4 (36.4%) 133 (63.3%) 77 (36.7%)
Age (years) Average ± S.D. 43.7 ± 14.1 50.5 ± 13.2 45.6 ± 12.6 38.3 ± 12.6 44.4 ± 17.3 46.0 ± 14.8
Anti-SARS-CoV2 IgG Positive Titer (Average ± SD) 5.0 ± 3.5 5.4 ± 3.3 4.8 ± 1.9 2.9 ± 2.0 4.2 ± 2.0 3.8 ± 1.8
Dengue or Chikungunya Specific IgM titer (DO/CO) Average ± SD 6.5 ± 3.0 6.1 ± 2.9 2.1 ± 1.9 2.1 ± 1.1 N.A. N.A.
�—Compared to the number of either Chikungunya (n = 7,349), Dengue. (n = 1,700) or Total samples tested (n = 7,370)
��—Compared to the total number of SARS-CoV2 IgG positive samples Chikungunya (n = 176), Dengue. (n = 85) or Total groups (n = 210).
N.A.–Not applicable.
https://doi.org/10.1371/journal.pone.0244937.t003
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IgM and Chikungunya IgM) increased from 0% to 73.8% (Fig 6A). Despite the increase in
SARS-CoV-2-only cases, specific IgG immunoreactivity index were not affected by the
absence or presence of IgM antibodies to both Dengue and Chikungunya, as depicted in
Fig 6B. However, when IgM immunoreactivity indexes for both Dengue and Chikungunya
were assessed either in the presence or absence of SARS-CoV-2 IgG antibodies, a signifi-
cant reduction in IgM immunoreactivity index was observed for Chikungunya/SARS--
CoV-2 samples (Fig 7A) but not for Dengue (Fig 7B).
Discussion
Co-infection cases of SARS-CoV-2 and other intracellular pathogens have been reported else-
where, ranging from arbovirus to protozoans [8, 13]. Considering that Malaria, Dengue, Chi-
kungunya, and SARS-CoV-2 acute symptoms share similar clinical features, distinguishing
them in co-endemic regions may pose a challenge with serious consequences [13, 14]. Data
presented here demonstrate that 210 (2.85%) out of 7,730 patients, suspected of having either
Dengue and Chikungunya infection, were positive for anti-SARS-CoV-2 IgG (Table 3), cor-
roborating with the hypothesis that covert SARS-CoV-2 misdiagnosis is a present threat in
Dengue and Chikungunya endemic regions [8]. Nevertheless, a high incidence (ranging from
40 to 73.8%) of covert SARS-CoV-2 cases was observed among patients initially suspected of
having either Dengue fever or Chikungunya, but tested negative for both arboviruses. It is
important to emphasize that 131 (62.4%) out of 210 SARS-CoV-2 positive patients displaying
symptoms compatible with arboviral infection were negative for either Dengue or Chikungu-
nya (Table 3), indicating that SARS-CoV-2 was not considered in the diagnostic strategy.
Reported elsewhere [8, 10, 15], occurrence of serological cross-reactivity between Dengue and
SARS-CoV-2 antibodies was not confirmed by our results (Table 1). Interestingly, 16 (7.6%)
SARS-CoV-2 IgG positive samples were collected between December, 2019 and February,
2020, showing that exposure to SARS-CoV-2 was already occurring prior to COVID-19 was
declared a global pandemic, and even before its presence was officially confirmed by the health
authorities in Brazil. To rule out the possibility that those earlier SARS-CoV-2 cases were due
to false-positive results, their samples were also screened for the presence of specific IgG to
both N and S proteins by a different assay, and 7 (43.8%) out of the 16 samples tested positive
(Table 4). Differences observed here, regarding Abbott’s CMIA and Snibe’s CLIA results, may
be justified by the fact that anti-N IgG response is known to appear earlier than the response
targeting the S protein [15].
Our data strongly supports the hypothesis that SARS-CoV-2 infection was overshadowed
by a concomitant Dengue and Chikungunya epidemic. Case #16, depicted on Table 4, illus-
trates how an existent arboviral outbreak may hinder the diagnosis of SARS-CoV-2 infection.
Briefly, a 43-year-old female patient, living in the city of Cachoeiro do Itapemirim, endemic
for both Dengue and Chikungunya (Fig 5), presented clinical symptoms suggestive of Dengue
fever on January 26, 2020. A blood sample (#1) was collected on February 3rd., testing negative
for anti-Dengue IgM. Symptoms persisted and another sample (#2) was collected on February
27th and gave a positive result for anti-Chikungunya IgM (Table 4). When samples #1and #2
were later screened, presence of anti-SARS-CoV-2 IgG antibodies was detected on sample #2,
suggesting that an acute SARS-CoV-2 infection was probably present and was missed when
Fig 2. A-C) Assessment of gender influence on immunoreactivity levels in Chikungunya, Dengue, and SARS-CoV-2 patients. A) Chikungunya
patients; B) Dengue patients; and C) SARS-CoV-2 patients. Categorical variables were compared using Fisher’s exact test and continuous variables
with the Mann-Whitney U test; �p<0.05; ��p<0.01. 2D) Evolution of SARS-CoV-2 positivity rate from December 2019 to June 2020; 2E and F)
Assessment of SARS-CoV-2 IgG immunoreactivity index (S/CO) categorized by: E) days post-symptoms onset, and F) grouped by age.
https://doi.org/10.1371/journal.pone.0244937.g002
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sample #1 was collected (Table 4). Such findings may help to explain why patients are diag-
nosed as Dengue fever at first and later confirmed to be COVID-19 cases [11, 16]. Therefore,
presumption of Dengue or Chikungunya infection without further investigation may result in
inadvertent omission of adequate standard of care for treatment and may ultimately facilitate
the expansion of SARS-CoV-2 transmission 2 [8, 10].
It has been shown elsewhere that, after symptoms onset, antibody immunoreactivity
indexes increase over time, with an enhanced clinical sensitivity of serological tests found�14
days after the beginning of clinical illness [15, 17, 18]. Analysis of anti-SARS-CoV-2 IgG S/CO
data by days post-symptoms onset showed no significant difference, suggesting that all 210
IgG-positive patients were exposed� 14 days before their blood samples were collected (Fig
2E). As a matter of fact, the earliest undiagnosed COVID-19 case dates back to December 18,
2019. Suspected of having Dengue Fever, our so called “patient zero”, tested positive for Den-
gue, and was only diagnosed positive for the presence of anti-SARS-CoV-2 IgG antibodies in
the present study (Table 4). This finding raises concerns, particularly because clinicians fre-
quently diagnose Dengue fever based only on the detection of IgM to Dengue virus, which
may persist for months after resolution of viral infection [19].
In the present work, specific anti-SARS-CoV-2 IgG immunoreactivity was assessed by a
highly specific and sensitive method (Abbott Laboratories SARS-CoV-2 IgG) CMIA [18, 20],
thus the likelihood that positive results were triggered by serologic cross-reactivity with other
coronaviruses or with arboviruses was negligible. According to different authors, cross-reactiv-
ity with other seasonal coronavirus, such as E229, OC43, HKU1, and NL63, was not observed
when COVID-19 serum samples were tested by Abbott Laboratories SARS-CoV-2 IgG CMIA
[21–23]. Occurrence of cross-reactivity between Dengue and SARS-CoV-2 antibodies [10, 12,
24], was not corroborated by results presented here as well as from other authors [25]. We
demonstrated that all 84 (100%) Dengue-positive samples, collected between 2009 and 2010,
tested negative for the presence of anti-SARS-Cov-2 IgG (Table 1; Fig 4). It is important to
point out that previous reports suggesting cross-reactivity between Dengue and SARS-CoV-2
antibodies were based on limited sample size and exclusively on data acquired using lateral
flow immunochromatographic rapid diagnostic test (RDT) [10, 12, 24]. In the early days of the
COVID-19 pandemic, serology results were primarily obtained from RDT, which, despite a
high specificity (�99%), present a lower sensitivity when compared to CLIA/CMIA [25–27];
explaining why accuracy and reliability of RDT for Dengue and SARS-CoV-2 diagnosis are
still so disputable [12, 24, 25, 28].
In addition to a high (2.85%) prevalence of patients with positive results for SARS-CoV-2
(Table 3), frequency of SARS-CoV-2-only cases (patients who are positive for anti-SARS--
CoV-2 IgG but negative for both Dengue IgM and Chikungunya IgM) was also significantly
elevated, comprising 73.8% of all samples tested in June 2020 (Fig 6A). Taken together these
results corroborates with previous findings from the stringent “test-track-trace” strategy,
which included large-scale PCR testing and extensive tracing technology, adopted by South
Korean health authorities. As reported here, data from a study conducted in Daegu, South
Korea, encountered a seroprevalence of 7.6%, with most of the IgG-positive individuals diag-
nosed as asymptomatic cases, indicating that the number of undiagnosed missing SARS-CoV-
2 infections were higher than previously expected [29].
Fig 3. Correlation between SARS-CoV-2 IgG immunoreactivity index (S/CO), and both: A) age distribution (years). The black dotted line
represents the cutoff point for the CMIA (S/CO = 1.4). B) time between symptoms onset and sample collection. No significant differences
were observed. Rho (ᴩ) = 0.019 (Fig 3A) and 0.1111 (Fig 3B).
https://doi.org/10.1371/journal.pone.0244937.g003
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Although, proposed by Verduyn et al (2020) [30] that early high IgM and IgG levels
observed in SARS-CoV-2 infection may increase disease severity in the case of Dengue co-
infection, this hypothesis did not find support in our data. As shown here, IgM index on Chi-
kungunya and SARS-CoV-2 co-infection samples was significantly reduced (p<0.0001) when
compared to Chikungunya infection alone (Fig 7A), and undistinguishable when Dengue and
Dengue/SARS-CoV-2 were compared (Fig 7B).
To our knowledge, this is the first study to investigate, with a robust sample size (n = 7,370)
and using highly specific and sensitive CMIA method, the hypothesis that covert SARS-CoV-2
infections are more frequent than previously expected in Dengue and Chikungunya hyperen-
demic regions. Our findings demonstrated that an existing positive IgM test result for either
Dengue or Chikungunya infections may prevent the early diagnosis of SARS-CoV-2 infec-
tions; since SARS-CoV-2 and arboviral diseases share similar features, the presence of a posi-
tive IgM result for either Dengue or Chikungunya may deceive clinicians to do not consider
SARS-CoV-2 as a potential cause for the observed symptoms. Although, the main limitation of
this study was the unavailability of paired nasopharyngeal swab samples, to confirm the
Fig 4. Assessment of pre-pandemic Dengue positive samples (PPS): A) Pre-pandemic samples (n = 84 samples) were
tested using Abbott’s Architect SARS-CoV-2 IgG CMIA, 42 samples were from the acute phase and another 42 paired
samples from the convalescent phase. The red dotted line represents the cutoff point for the CMIA (S/CO = 1.4); B)
SARS-CoV-2 IgG immunoreactivity index (S/CO) displayed by acute samples and convalescent samples from Dengue
positive patients. No significant differences were observed.
https://doi.org/10.1371/journal.pone.0244937.g004
Table 4. Characteristics the first 16 SARS-CoV-2 positive cases.
Case
#






IgM level S/CO IgM level S/CO IgG level S/CO IgG level AU/mL IgM level AU/mL
1 60 Female Vitória 12/18/19 NP NP + 4.31 + 2.42 - 0.47 - 0.45
2 8 Female Vila Velha 12/27/19 + 1.25 NP NP + 2.11 - 0.26 - 0.24
3 53 Female Vitória 1/15/20 - 0.33 NP NP + 1.57 + 3.16 - 0.23
4 51 Female Vila Velha 1/21/20 + 11.82 + 1.16 + 6.78 + 3.16 + 1.17
5 40 Male Vitória 1/22/20 + 2.18 NP NP + 2.70 + 1.54 - 0.38
6 62 Female Guarapari 1/23/20 + 2.11 NP NP + 3.43 + 4.66 - 0.47
7 61 Female Vitória 2/6/20 + 11.93 NP NP + 3.34 + 1.81 - 0.1
8 62 Male Vitória 2/7/20 + 1.21 NP NP + 1.48 - 0.83 - 0.67
9 63 Male Vitória 2/13/20 + 4.94 NP NP + 3.68 - 0.1 - 0.44
10 35 Female Serra 2/13/20 ? 0.99 NP NP + 2.24 - 0.41 - 0.02
11 46 Female C. de
Itapemirim
2/14/20 + 11.73 NP NP + 2.02 - 0.19 - 0.5
12 50 Female Vitória 2/14/20 + 10.5 NP NP + 2.13 + 2.58 - 0.39
13 0.7 Male Guarapari 2/17/20 NP NP - 0.05 + 2.12 - 0.09 - 0.39
14 44 Female Vitória 2/19/20 ? 0.99 NP NP + 4.35 + 4.44 - 0.3
15 63 Male Colatina 2/19/20 NP NP - 0.61 + 2.17 - 0.12 - 0.34
16 43 Female C. de
Itapemirim
2/3/20 NP NP - - - 0.16 - 0.08 - 0.29
2/27/20 + 11.12 NP NP + 1.93 - 0.08 - 0.21
NP—Not performed.
https://doi.org/10.1371/journal.pone.0244937.t004
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Fig 5. Distribution of the 210 positive cases of SARS-CoV-2 in the state of Espı́rito Santo. The red and black location markers represent
the date of sample collection. The municipalities in dark blue represent the localities with cases of Chikungunya only, and municipalities in
light blue where both Chikungunya and Dengue.
https://doi.org/10.1371/journal.pone.0244937.g005
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Fig 6. A) Frequency of positive SARS-CoV-2 cases over time (December, 2019 to June, 2020). SARS-CoV-2 cases were grouped in
SARS-CoV-2-only (red bars), co-infected with Chikungunya (blue bars) or co-infected with Dengue virus (green bars). B) SARS-CoV-2 IgG
immunoreactivity index (S/CO) was compared between groups SARS-CoV-2-only (red dots), and co-infected with Chikungunya (blue dots)
or Dengue (green dots). No significant differences were observed.
https://doi.org/10.1371/journal.pone.0244937.g006
PLOS ONE Covert SARS-CoV-2 positive cases among Dengue and Chikungunya patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0244937 January 6, 2021 17 / 21
PLOS ONE Covert SARS-CoV-2 positive cases among Dengue and Chikungunya patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0244937 January 6, 2021 18 / 21
presence of the virus, our results suggest that individual were exposed to SAR-CoV-2 prior to
February, 2020, and that these covert cases may have contributed to the fast expansion of
SARS-CoV-2 outbreak in Brazil.
In conclusion, our study reiterates the challenge associated with SARS-CoV-2 diagnose in
endemic areas for arboviruses. Therefore, enforcement of vigilant awareness and systematic
investigation is essential for appropriate treatment and control of SARS-CoV-2. Finally, data
shown here raise the alert that in arboviral endemic regions, SARS-CoV-2 infection must be
always considered, regardless of the existence of a previous positive test result for Dengue or
Chikungunya and/or the absence of respiratory symptoms.
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